Divided FTC Okays Mylan-Upjohn Merger But Election Outcome Could Impede Future Deals
Executive Summary
Commissioners vote 3-2 that Mylan and Pfizer’s Upjohn can combine after divesting seven products; dissenting votes focus on price fixing allegations as commissioners Chopra and Slaughter criticize majority for not addressing government’s case against Pfizer and Mylan. Former FTC attorneys note that if Biden wins the presidential election, he could nominate one of the dissenters to FTC chair and give more traction to their views.
You may also be interested in...
FTC Commissioner Changes Could Impact Pharma Mergers, Scrutiny Of Biosimilars Uptake
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.
OTC Decisions August-October: More Providers Enter Diclofenac, Lansoprazole, Loratadine Markets
CDER’s August-September OTC application approvals are highlighted by Arbor Pharmaceuticals’ ivermectin 0.5% lice treatment. Orange Book changes also include four firms’ approvals for labeling to market generic equivalents of Voltaren Arthritis Relief launched as an OTC switch since earlier in 2020.
What’s Next? Five Things To Look Out For In November
In November, Generics Bulletin will host its seventh annual Global Generics & Biosimilars Awards, while the long-awaited merger of Mylan and Pfizer’s Upjohn is set to complete and third-quarter financial results dominate the landscape.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: